CTOs on the Move

Synaptogenix

www.synaptogen.com

 
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.synaptogen.com
  • 1185 Avenue of the Americas 3rd Floor
    New York, NY USA 10036
  • Phone: 973.242.0005

Executives

Name Title Contact Details

Funding

Synaptogenix raised $14M on 01/21/2021
Synaptogenix raised $12.5M on 06/14/2021

Similar Companies

Slingshot Biosciences

Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.

NewLeaf Symbiotics

NewLeaf Symbiotics® is at the forefront of sustainable agriculture technology, with a singular focus on the identification, development and commercialization of the beneficial microbes called pink pigmented facultative methylotrophs (M-trophs). This new class of agricultural microbes is helping transition agricultural products and production to deliver better quality crops, with less impact on the environment — a win-win for growers and those of us who depend on their success.

Harbor Therapeutics

Harbor Therapeutics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cognate BioServices

Cognate BioServices is a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapies. We pride ourselves in the level of quality and experience we bring to the table. Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, organizations and institutions. Cognate provides a unique combination of custom services to companies across all points of clinical and commercial development ranging from early preclinical studies, to mid phase trials and product scale-up though later stage clinical trials and bridging into commercial manufacturing. Cognate applies the know-how and expertise of its business, scientific and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms from start to finish.

NuProbe

NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world`s greatest challenges — non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capabilities in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings licensed by Wyss Institute, Harvard University.